News

Windlas Biotech announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 6.3 per equity Share (i.e. 126%) , subject to the approval of the shareholders.

Net profit of Windlas Biotech declined 1.78% to Rs 15.99 crore in the quarter ended March 2026 as against Rs 16.28 crore during the previous quarter ended March 2025. Sales rose 17.66% to Rs 238.50 crore in the quarter ended March 2026 as against Rs 202.71 crore during the previous quarter ended March 2025.For the full year,net profit rose 8.97% to Rs 66.46 crore in the year ended March 2026 as against Rs 60.99 crore during the previous year ended March 2025. Sales rose 18.98% to Rs 904.09 crore in the year ended March 2026 as against Rs 759.88 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales238.50202.71 18 904.09759.88 19 OPM %10.6012.60 -11.5912.38 - PBDT28.1629.16 -3 117.72107.74 9 PBT20.1620.82 -3 86.9879.76 9 NP15.9916.28 -2 66.4660.99 9 Powered by Capital Market - Live News

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 21 May 2026.

The board of Windlas Biotech at its meeting held on 17 April 2026 has approved buyback of up to 4,70,000 fully paid up equity shares of the company (representing 2.23% of the paid up equity share capital) at a price of Rs 1,000 per equity share for an aggregate amount not exceeding Rs 47 crore.

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 17 April 2026.